Get the Stockscreener App
2.69
3.07%
0.08
Inhibikase Therapeutics Inc stock is traded at $2.69, with a volume of 71,626.
It is up +3.07% in the last 24 hours and up +113.49% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$2.61
Open:
$2.62
24h Volume:
71,626
Relative Volume:
0.17
Market Cap:
$174.30M
Revenue:
-
Net Income/Loss:
$-19.20M
P/E Ratio:
-0.6451
EPS:
-4.17
Net Cash Flow:
$-15.98M
1W Performance:
+1.89%
1M Performance:
+113.49%
6M Performance:
+93.53%
1Y Performance:
+161.17%
1-Day Range:
$2.61
$2.71
1-Week Range:
$2.37
$2.80
52-Week Range:
$0.7981
$3.82
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
678-392-3419
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey
Director Arvind Kush Acquires 145,000 Shares of Inhibikase Thera - GuruFocus.com
Inhibikase therapeutics director Amit Munshi buys $500k in shares - Investing.com India
Inhibikase therapeutics director Amit Munshi buys $500k in shares By Investing.com - Investing.com Australia
Inhibikase Therapeutics director Bellini acquires $2m in stock - Investing.com India
Inhibikase Therapeutics director Bellini acquires $2m in stock By Investing.com - Investing.com South Africa
Inhibikase therapeutics director Kush Arvind buys $198,650 in stock - Investing.com
Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance
Inhibikase (IKT) Stock Climbs After-Market Following Key Financing - Stocks Telegraph
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therape - GuruFocus.com
Inhibikase Therapeutics stock rises after pricing $110M private offering - MSN
IKTInhibikase Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Inhibikase Therapeutics Announces Closing of up to $275 - GlobeNewswire
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Inhibikase Therapeutics’ $110 Million Private Placement - Global Legal Chronicle
Analyzing the Impact of Earnings Reports on Inhibikase Therapeutics Inc Inc. (IKT) Price Performance - The InvestChronicle
500: Something went wrong - Investing.com
Inhibikase Therapeutics Secures $110M for Drug Development - Yahoo Finance
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) expanding its growth trajectory ahead - SETE News
Inhibikase Therapeutics, Inc. Announces Pricing of $110 Million Private Placement - Marketscreener.com
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline - Yahoo Finance
Inhibikase Therapeutics Inc. (NASDAQ:IKT) Stock Hits 5-Month High On Private Placement - DRP Journal
Inhibikase Therapeutics Inc’s Banking’s 100-Day Moving Average at 1.4198: Will the Stock Break Through? - The InvestChronicle
IKT’s price-to-free cash flow ratio: What it means for investors - US Post News
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today - Benzinga
Inhibikase Therapeutics announces $110 million financing - Investing.com
Inhibikase Therapeutics Announces Pricing of $110 Million - GlobeNewswire
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension - Quantisnow
Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World
Ieq Capital LLC Purchases 2,616 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia
J.W. Cole Advisors Inc. Has $225,000 Holdings in InvenTrust Properties Corp. (NYSE:IVT) - Defense World
Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business - Yahoo Finance
Innovative Industrial Properties (NYSE:IIPR) Hits New 1-Year High at $137.91 - MarketBeat
Had You Purchased Incyte in 2004, Here’s Your Result - MMJ Stock Watch
INVX underperforms with a -2.86 decrease in share price - US Post News
Ratios Uncovered: Breaking Down Ironwood Pharmaceuticals Inc (IRWD)’s Trailing Twelve Months Metrics - The Dwinnex
Incyte Corp. (INCY) looking to reclaim success with recent performance - SETE News
InvenTrust Properties Corp. (NYSE:IVT) Short Interest Down 5.5% in August - Defense World
Get in on Invesco Ltd’s (IVZ) buy-in window today! - SETE News
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
Imugene (ASX:IMU) achieves FDA Orphan Drug Designation for VAXINIA - Kalkine Media
Incyte stock downgraded amid looming patent cliff concerns By Investing.com - Investing.com Canada
Insider Selling: InnovAge Holding Corp. (NASDAQ:INNV) Insider Sells 4,372 Shares of Stock - Defense World
InnovAge holding corp. executive sells over $70k in stock By Investing.com - Investing.com UK
Incyte DowngradedAnalyst Notes Intense Competition, Particularly In Larger Markets - Yahoo Finance
Incyte (NASDAQ:INCY) Stock Price Down 1.9% - MarketBeat
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):